AI assistant
Sending…
Vaxcyte, Inc. — Director's Dealing 2022
Mar 16, 2022
31100_dirs_2022-03-15_2cffb44f-bf47-400b-8a3a-d473b514ddb8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2022-03-11
Reporting Person: Fairman Jeff (VP, Research)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-03-11 | Common Stock | S | 10000 | $25.50 | Disposed | 331227 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 16629 | Direct |
| Common Stock | 50000 | Indirect |
Footnotes
F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
More from Vaxcyte, Inc.
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 23
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Regulatory Filings
2026
Feb 24